Developing a Safer Approach to Treat Pain and Inflammation
EicOsis is transforming inflammation treatment with a novel approach that restores the body’s natural ability to heal—safely and effectively.
Pain and Inflammation
Understand the unmet needs of those suffering from pain or inflammatory conditions, and how EicOsis is working to make a difference in their lives.
Our Approach
Learn how our novel technology, targeting the soluble Epoxide Hydrolase, can help us develop new safe and effective oral analgesics and anti-inflammatories.
Media & Investors
Spread the news on EicOsis’s progresses and learn about our commitment to to improve the lives of those suffering from pain and inflammation.
Addressing the Urgent Need for Better Chronic Pain Drugs and Fighting the Opioid Crisis
Chronic pain affects 100 million Americans and causes a substantial physical and emotional impact on their lives. Current treatments for pain are insufficient, and patients are often prescribed opioids. Increased prescription of opioids has led to a widespread public health emergency, the US Opioid Crisis. There is an unmet need for safe, non-addictive and effective pain medications that can help pain patients and fight the US Opioid Crisis.
At EicOsis we are developing a new approach to treat pain and inflammation by inhibiting the soluble Epoxide Hydrolase (sEH), a key regulatory enzyme. Inhibiting sEH increases the levels of naturally occurring anti-inflammatory and pain-relieving compounds. Our first drug candidate is currently undergoing Phase 1 human clinical trials. Learn more about EicOsis Human Health.
Enrollment Underway in EicOsis Spinal Cord Injury Neuropathic Pain Trial
EicOsis Human Health is actively enrolling participants in a clinical trial evaluating EC5026 in patients with neuropathic pain following traumatic spinal cord injury. The study is being conducted in Augusta, Georgia, under the leadership of Dr. Laura Carbone, Division Chief of Rheumatology at Wellstar MCG Health. The trial is designed to evaluate the safety and tolerability of EC5026 in this patient population while also exploring its potential as a novel non-opioid treatment for neuropathic pain. The trial is funded by the U.S. Department of Defense and represents an important step in EicOsis’ clinical development program for EC5026 in neuropathic pain conditions.
-
Alzheimer’s Association Part the Cloud Award Will Support Phase 1b Study of EC5026 in Alzheimer’s Disease
The $1M award to Dr. Walter Swardfager, from Sunnybrook Research Institute (Toronto, Canada), will support a proof-of-mechanism clinical trial evaluating EicOsis’ soluble epoxide hydrolase inhibitor in biomarker-confirmed early Alzheimer’s disease. The trial is expected to start in 2027.
“We are thrilled that the Alzheimer’s Association has recognized the potential of soluble epoxide hydrolase inhibition as a therapeutic approach for Alzheimer’s,” said Cindy Brown, Ph.D., CEO and co-founder of EicOsis Human Health. “Neuroinflammation is increasingly recognized as an important component of Alzheimer’s disease, and this study gives us an opportunity to determine whether targeting soluble epoxide hydrolase with EC5026 can meaningfully improve inflammatory and neurodegenerative biomarkers in patients.” More details can be accessed here.
EicOsis Highlights EC5026 at the 2026 Pain Therapeutics Summit
Cindy Brown, CEO and Co-Founder of EicOsis Human Health, presented at the 2026 Pain Therapeutics Summit, held September 28–29 in the San Francisco Bay Area. The summit brought together leaders from industry and academia to discuss advances in pain therapeutics, drug development, mechanisms of pain, translational research, biomarkers, and emerging treatment strategies.
Cindy highlighted EicOsis’ clinical development of EC5026, a first-in-class oral soluble epoxide hydrolase (sEH) inhibitor, and its potential as a novel non-opioid approach to treating pain and neuroinflammation.
EicOsis was pleased to join this community of researchers and drug developers working to advance safer and more effective treatments for patients living with pain. Learn more about the Pain Therapeutics Summit here.
-
EicOsis Completes First Cohort in Phase 1b Parkinson’s Disease Trial
EicOsis has completed the first cohort of its Phase 1b proof-of-concept clinical trial evaluating EC5026 in people with Parkinson’s disease.
The study is being conducted at UC Davis Health with funding from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and is designed to explore the safety, pharmacokinetics, target engagement and exploratory efficacy of EC5026 in this patient population.
EC5026 is a first-in-class oral soluble epoxide hydrolase (sEH) inhibitor being developed as a novel approach to modulating neuroinflammation and related disease mechanisms.
Enrollment of the second (higher dose) cohort is expected to begin in October 2026, with completion of the full study anticipated in the first half of 2027.
Completion of the first cohort represents an important milestone in EicOsis’ efforts to advance EC5026 into clinical studies addressing neuroinflammatory and neurological disorders with significant unmet medical need.
-
EicOsis Publishes Safety and Pharmacokinetic Results from Two Phase 1a Clinical Trials
EicOsis recently published the results for two Phase 1a clinical trials in healthy volunteers. The trials evaluated the safety and pharmacokinetic profile of EC5026 in a single-ascending dose (SAD) study and a fed-fasted study. EC5026 was well tolerated in healthy volunteers at single doses up to 24 mg and demonstrated a favorable pharmacokinetic profile for once-daily oral dosing. The paper can be accessed here.
-
EicOsis Publishes Safety and Pharmacokinetic Results from Two Phase 1a Clinical Trials
EicOsis recently published the results for two Phase 1a clinical trials in healthy volunteers. The trials evaluated the safety and pharmacokinetic profile of EC5026 in a single-ascending dose (SAD) study and a fed-fasted study. EC5026 was well tolerated in healthy volunteers at single doses up to 24 mg and demonstrated a favorable pharmacokinetic profile for once-daily oral dosing. The paper can be accessed here.
-
Dr. Bruce Hammock Inducted as Fellow of the California Academy of Sciences
Bruce Hammock, Distinguished Professor and EicOsis founder, is a newly inducted Fellow of the California Academy of Sciences (CAS). Hammock was inducted along with 13 other Fellows on Nov. 14 during the annual Fellowship meeting.
“We’re proud to announce 2023’s distinguished pool of new Fellows—each of their contributions to science and society represent major advancements in their respective fields” says Academy Dean of Science and Research Collections Shannon Bennett, Ph.D. “Our Fellows body is a group of future thinkers and innovators whose leadership inspires the next generation of scientists, science educators, story-tellers and change-makers. We look forward to forging a future with our new Fellows that advances the Academy’s mission to regenerate the natural world through science, learning, and collaborative partnerships.”
-
Landmark PNAS Publication Establishes a Potential Role of Soluble Epoxide Inhibitors for Traumatic Brain Injury
A landmark study indicates that the liver plays an important neuroprotective role in the pathophysiology of traumatic brain injury (TBI) and suggests that exploiting this natural role may represent a promising therapeutic strategy for TBI. The breakthrough follows a discovery from investigators at South China University of Technology, Guangzhou, and UC Davis, and was published in the Proceedings of the National Academy of Sciences (PNAS) this week. The abstract can be accessed here.
-
Dr. Bruce Hammock receives prestigious international award
Distinguished professor and EicOsis founder Dr. Bruce Hammock is part of the Who’s Who “click-chemistry team” that won the Royal Society of Chemistry’s Horizon Team Award for advancing chemistry and “pushing the boundaries of science.” The Horizon Prizes “highlight the most exciting, contemporary chemical science at the cutting edge of research and innovation.” The Award was announced on June 2021.
Photo by Kathy Keatley Garvey
-
A Possible Biomarker of Severe COVID-19
In an article published in Frontiers of Physiology, Dr. Cindy McReynolds and colleagues show how certain fatty acids in the blood of COVID-19 patients may predict severity. The compounds, known as leukotoxins and leukotoxin diols, originate from linoleic acid, the most abundant dietary fat. This discovery may offer a target for treatment.
-
Epoxide hydrolase inhibitor reduces neuroinflammation in a model of Alzheimer’s disease
An article published in Science Translational Medicine shows how an sEH inhibitor can reduce neuroinflammation in a mouse model of Alzheimer’s disease, making sEH inhibitors an attractive drug class for further development as potential treatment for Alzheimer’s disease.
-
Dr. William Schmidt chairs the 14th Annual Pain Therapeutics Summit
The 14th Annual Pain Therapeutics Summit, who’s Chairperson is EicOsis’s Vicepresident for Clinical Development William Schmidt, took place virtually in November 2020. Leading figures across academia, industry and the public sector gathered to focus on identifying and advancing novel pain drugs through clinical development and commercialization. Next year’s summit is scheduled for November 1-2, 2021 in Washington, DC.
-
Dr. Bruce Hammock receives Lifetime Innovation Award
Dr. Hammock, Distinguished Professor in the Department of Entomology and Nematology at UC Davis, received the UC Davis Chancellor Lifetime Achievement Award in Innovation in June 2020. This award recognizes researchers whose career accomplishments include innovations leading to a long-term positive impact on the lives of others and who are an inspiring influence for other innovators.
EicOsis Has Been Awarded over 20 Million in Competitive Grants and Funding
EicOsis is advancing its first drug candidate to human clinical trials with the support of funding from federal grants and angel investors.
January, 2025 – EicOsis announces $2M Michael J Fox Foundation award to study new approach for treating Parkinson’s disease.
January, 2024 – EicOsis receives renewal of NIDA/NIH HEAL Initiative grant, progressing to clinical phase.
April, 2022 – EicOsis receives an SBIR grant to study inhibition of the soluble epoxide hydrolase (sEH) enzyme in patients with arrhythmogenic cardiomyopathy. (ACM)
February, 2021 – Veterans Affairs investigator recibes Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award from the Department of Defense to conduct clinical trial of EC5026 for neuropathic pain
October, 2019 – EicOsis receives SBIR grant award from NCI/NIH
October, 2019 – EicOsis receives $15 M from NIDA/NIH as part of the HEAL Initiative
March, 2019 – EicOsis raises funding for Phase 1 clinical development from Open Philanthropy
January, 2019 – EicOsis receives $4 M from NIH Blueprint for Neuroscience Research to advance oral analgesic to Phase 1 clinical trials for neuropathic pain
Learn more about our funding sources.
